Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
Cullinan Oncology (Nasdaq: CGEM) announced its participation in upcoming investor conferences. CFO Jeff Trigilio will present at the HC Wainwright Global Investment Conference on September 13, 2022, at 2:00 p.m. EDT. CEO Nadim Ahmed will engage in a fireside chat at the Morgan Stanley Healthcare Conference on September 14, 2022, at 10:35 a.m. EDT. Live webcasts for both events will be accessible via the Company’s investor relations website, enhancing investor engagement and transparency.
- None.
- None.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Company management will participate in the following investor conferences:
- Chief Financial Officer Jeff Trigilio will present at the HC Wainwright Global Investment Conference on September 13, 2022 at 2:00 p.m. EDT
- Chief Executive Officer Nadim Ahmed will participate in a fireside chat at the Morgan Stanley Healthcare Conference on September 14, 2022 at 10:35 a.m. EDT
Live webcasts of the HC Wainwright presentation and Morgan Stanley fireside chat will be available via the Events section of the Company’s investor relations website at https://investors.cullinanoncology.com/news-events/events.
About Cullinan Oncology
Cullinan Oncology, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and biologics to create differentiated ideas, identify unique targets, and select the optimal modality to develop transformative therapeutics across cancer indications. Powered by our novel research model, we push conventional boundaries from candidate selection to cancer therapeutic, applying rigorous early experimentation to fast-track only the most promising assets to the clinic and ultimately commercialization. As a result, our diversified pipeline is strategically built with assets that activate the immune system or inhibit key oncogenic drivers across a wide range of modalities, each with the potential to be the best or first in their class.
Our people possess deep scientific expertise, seek innovation openly, and exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients with cancer. Learn more about our Company at www.cullinanoncology.com, and follow us on LinkedIn and Twitter.
Contacts:
Investor Relations
Chad Messer
+1 203.464.8900
cmesser@cullinanoncology.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinanoncology.com
FAQ
What is the date and time of Cullinan Oncology's presentation at the HC Wainwright Global Investment Conference?
When will the CEO of Cullinan Oncology participate in the Morgan Stanley Healthcare Conference?
Where can I watch the live webcasts of Cullinan Oncology's investor presentations?
What is the stock symbol for Cullinan Oncology?
